SOPHiA GENETICS CTO granted options and RSUs

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported equity awards and a correction to his reported holdings.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported equity awards and a correction to his reported holdings. He received a share option for 119,760 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036, and 82,136 restricted stock units representing future ordinary shares.

The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The amendment also corrects his ordinary share holdings after the reported transactions to 207,949 shares, instead of 82,136 shares previously reported due to an error.

Insider Trade Summary

Grant/Award: 201,896 shares

Grant/Award 2 txns

Insider Verma Abhimanyu

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	119,760	$0.00	$0.00
Grant/Award	Ordinary Shares	82,136	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 119,760 contracts (Direct); Ordinary Shares — 207,949 shares (Direct)

Footnotes (3)

1. F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
2. F2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 82,136 ordinary shares due to an inadvertent error. The correct amount is 207,949 ordinary shares.
3. F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Key Figures

Share option grant: 119,760 shares at $5.04 RSU grant size: 82,136 RSUs Post-transaction holdings: 207,949 ordinary shares +2 more

5 metrics

Share option grant 119,760 shares at $5.04 Option to buy ordinary shares, granted April 2, 2026

RSU grant size 82,136 RSUs Each RSU represents one ordinary share

Post-transaction holdings 207,949 ordinary shares Amount of securities beneficially owned after reported transactions

Option expiration April 2, 2036 Expiration date of share option grant

Initial vesting date April 2, 2027 25% vesting date for both RSUs and options

Key Terms

restricted stock unit ("RSU"), 2021 Equity Incentive Plan, share option, vest

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."

2021 Equity Incentive Plan financial

"RSU grant made under the Issuer's 2021 Equity Incentive Plan."

share option financial

"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"

vest financial

"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SOPHiA GENETICS (SOPH) report for Abhimanyu Verma?

Abhimanyu Verma received two equity awards: a share option for 119,760 ordinary shares at $5.04 per share and a grant of 82,136 restricted stock units. These awards increase his potential and actual equity exposure to SOPHiA GENETICS SA over time.

How many SOPHiA GENETICS (SOPH) shares does Abhimanyu Verma hold after the Form 4/A amendment?

After the reported transactions, Abhimanyu Verma beneficially owns 207,949 ordinary shares. The Form 4/A corrects a prior filing that had mistakenly reported this amount as 82,136 shares, explicitly noting the earlier figure resulted from an inadvertent error.

What are the terms of the SOPHiA GENETICS (SOPH) share option granted to Abhimanyu Verma?

The share option covers 119,760 ordinary shares at an exercise price of $5.04 per share and expires on April 2, 2036. It vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, contingent on continued service.

How do the RSUs granted to Abhimanyu Verma at SOPHiA GENETICS (SOPH) vest?

The 82,136 RSUs vest over time, starting with 25% on April 2, 2027. The remaining 75% vests in equal quarterly installments through April 2, 2030, conditioned on his continued service, with each RSU representing one ordinary share upon settlement.

Why did SOPHiA GENETICS (SOPH) file an amended Form 4/A for Abhimanyu Verma?

The amended Form 4/A corrects the amount of ordinary shares beneficially owned after the reported transactions. A prior Form 4 had inadvertently reported 82,136 shares; the amendment clarifies the correct post-transaction amount is 207,949 ordinary shares held by Abhimanyu Verma.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/08/2026 - 08:46 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verma Abhimanyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/03/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/02/2026		A		82,136(1)	A	$0	207,949(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.04	04/02/2026		A		119,760		(3)	04/02/2036	Ordinary Shares	119,760	$0	119,760	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 82,136 ordinary shares due to an inadvertent error. The correct amount is 207,949 ordinary shares.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Abhimanyu Verma	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)